Last updated: May 29, 2026
Who supplies mavorixafor (X4Pharma/X4PA4) for clinical and commercial use?
Mavorixafor is the investigational small-molecule antagonist targeting the chemokine receptor CXCR4. Publicly accessible supplier intelligence is limited in this dataset; a complete, verified mapping of contract manufacturers, API suppliers, and packaging/finish suppliers cannot be produced here without introducing inaccuracies.
Which companies manufacture mavorixafor API (active pharmaceutical ingredient) and intermediates?
A verified list of mavorixafor API manufacturers and intermediate suppliers is not available in the provided information set. Building a supplier roster would require reliance on non-cited, potentially incorrect identifiers across jurisdictions and development stages.
Who are the contract manufacturing organizations (CMOs) for mavorixafor drug product?
A complete CMO/finished-dose supplier set for mavorixafor tablets or other dosage forms is not available in the provided information set. Without verified sourcing artifacts (e.g., FDA facility listings tied to the specific NDA/BLA/ANDA, or cited supplier disclosures), supplier naming would be speculative.
What is the Orange Book status of mavorixafor and does it constrain suppliers?
Mavorixafor is not represented in this dataset with a trackable Orange Book entry, and no FDA-listed, product-specific exclusivity or market authorization status is provided here. Without that, supplier constraints derived from listed approvals cannot be stated.
Does mavorixafor have an FDA approval that determines qualified manufacturing sites?
No FDA approval record or facility-level manufacturing authorization is provided in the dataset. As a result, supplier-to-facility linkage through FDA approvals cannot be completed.
Which CXCR4 program supply relationships affect mavorixafor availability (R&D vs launch)?
Mavorixafor supply relationships depend on whether the drug is in clinical supply mode or commercial scale. The dataset does not provide stage-specific supply chain disclosures (clinical batch suppliers, clinical material repackage partners, or scale-up CMOs), so those relationships cannot be enumerated reliably.
How do suppliers differ between clinical supply and commercial-scale production for mavorixafor?
A stage comparison requires named suppliers by phase (e.g., IND material API CMOs vs commercial API/DP CMOs). No phase-by-phase supplier list is present in the provided information set, so a defensible comparison cannot be produced.
Are there known tender awards or procurement disclosures for mavorixafor manufacturing?
No tender, procurement, or contract award information is included in this dataset for mavorixafor manufacturing or supply.
Key Takeaways
- A verified supplier roster for mavorixafor (API manufacturers, intermediates, CMOs, and finished-dose packaging/finish partners) cannot be produced from the provided information.
- No FDA facility-level manufacturing authorization data is included here to anchor supplier naming.
- No Orange Book status is included here to derive post-approval supplier constraints.
FAQs
-
Is mavorixafor manufactured by the same companies that supply other CXCR4 antagonists?
Not determinable from the provided data.
-
Who are the typical API suppliers for CXCR4 antagonists like mavorixafor?
Not determinable from the provided data.
-
Does mavorixafor use contract packaging partners in clinical trials?
Not determinable from the provided data.
-
How can mavorixafor suppliers be validated using FDA records?
Not determinable from the provided data.
-
Are there supplier dependencies that create single-source risk for mavorixafor?
Not determinable from the provided data.
References
(No sources were provided in the input.)
